Introduction
Alzheimer disease (AD) is a slowly progressing neurodegenerative disorder characterized by the misfolding, aggregation and gain of toxicity of amyloid-f3 (Af3) and tau in the brainY Aggregated Af3, in the form of densely packed fibrils, accumulates extracellularly in structures known as amyloid plaques. The tau aggregates also correspond to tightly packed filaments, but in contrast to plaques, they accumulate intracellularly in diseased neurons, where they are known as neurofibrillary tangles (NFTs). The term paired helical filament, or PHF, is often used to describe the individual tau filaments found in NFTs.
Af3 comprises a family of ~40 amino acid long peptide cleavage products of the transmembrane amyloid precursor protein and has no known essential function in normal physiology, but has long been regarded as a primary cause of ADY The original focus on large, fibrillar Af3 aggregates as possible causative agents for the memory and cognitive decline associated with AD has gradually shifted over the past decade to the realization that smaller, soluble Af3 oligomers are more relevant culprits. Compared with fibrillar Af3, soluble Af3 oligomers correlate better with neurotoxicity in vivo and are far more toxic than Af3 fibrils to cultured neurons. 5 -12 Tau was discovered nearly 40 years ago as a microtubule-associated protein (MAP) that stimulates tubulin polymerization,13 but it was not until a decade later that its presence in NFTs was first described. 14 -1G Surprisingly, beyond its generic MAP function as a stimulator of microtubule (MT) assembly, the only known specific function of tau is that it impedes the movement of kinesin MT motor proteins and their attached cargoes along MTs. 17-20 Historically, tau has received much less attention than Af3 in the AD field, despite the fact that a spectrum of neurodegenerative disorders known collectively as non-Alzheimer tauopathies are invariably characterized by PHF accumulation in the brain and can be caused by any of dozens of tau mutations. 21 PHF tau is abnormally phosphorylated at dozens of sites,22 some of which appear in vivo in both human AD cases and transgenic mice before the tau assembles into filaments. 23 About three decades after Prusiner first described prion driven infection in Creutzfeldt-Jacob disease 24 and speculated that a similar infectious process may apply to AD,25 a recent wave of evidence has demonstrated striking biochemical and cell biological similarities between AD and classical prion diseases. In contrast to PrP-based disorders, such as mad cow disease, scrapie and kuru, AD does not appear to be communicable between individuals, but a growing body of data indicate that misfolded, toxic oligomers of Af3 and tau spread through the brain from neuron to nearby neuron much much like misfolded Prp.25-32 For both Af38,33 and tau,34-38 moreover, misfolded forms of the peptide or protein can be taken up by neurons containing otherwise normal Af3 or tau, which as a result then misfold, become toxic and spread to other neurons.
In In contrast to plaques, abnormal tau first appears in proximal axons within the locus coeruleus,54 when it becomes immunoreactive with the AT8 monoclonal antibody, which detects tau phosphorylated at S202 and T205. 23 Evidently, tau at this stage has not yet assembled into PHFs, but instead is in a soluble, pre-NFT state. As AD progresses from pre-symptomatic to clinically detectable stages, the pattern of AT8-positive tau expands first to distal axonal and somatodendritic compartments within affected locus coeruleus neurons, and then sequentially to the entorhinal cortex (EC), dentate gyrus, CAl region of the hippocampus and the neocortex, Superimposed on this spreading of abnormal tau is its gradual acquisition of additional phosphoepitopes that are diagnostic of diseased neurons, and its conversion into PHFs,34 Interestingly, despite compelling evidence that Af3 is upstream of tau in AD pathogenesis,5,9,11 ,39,45-52 abnormal, pre-NFT tau is usually detectable before plaques,55.56 This may symbolize that soluble, oligomeric Af3, rather than plaques, provoke tau pathology, and that the pattern of plaque spreading simply reflects net rates of insoluble Af3 accumulation within various regions of brain over time. Two groups, using very similar approaches, recently published compelling experimental evidence that the spatiotemporal spread of tau in AD brain also involves transfer of tau from neuron to neuron along defined synaptic circuits,36,38 Both groups targeted expression of a human tau transgene specifically in the EC of mice. In both cases, the transgene encoded tau with a P30lL 15 Prion mutation that adopts an AD-like phosphorylation profile, forms PHFs and causes the non-Alzheimer tauopathy, FTDP-17, with full penetrance in humans,57,58 As the mice aged, they showed progressive tau pathology that began in the EC and subsequently followed the same path of axonal circuitry into the hippocampus as seen in human AD. Notably, this occurred without any detectable expression of human tau mRNA or protein outside of the EC. In other words, the toxic, mutant human tau that was expressed exclusively in the EC caused the endogenous mouse tau to misfold and become toxic, and then spread along synaptic circuits to the hippocampus, Besides confirming that tau pathology spreads along pre-determined, interconnected, neuroanatomical tracks, these data imply a prion-like process whereby misfolded "bad" tau can provoke the toxic misfolding of "good" tau, One important issue that remains to be determined is the mode of neuron-to-neuron transmission of misfolded tau, For example, the available data do not discriminate among models in which toxic tau is transferred from diseased to healthy neurons at synapses, via cycles of exocytosis and endocytosis, via intercellular bridges or by some combination of these or other potential mechanisms that can be imagined,
Af3 as a Prion
While progression of Af3 aggregation in human AD brain has fueled speculation of prionlike mechanisms of misfolding, recent in vivo and in vitro data have provided direct evidence for prion activity of Af3, and have suggested specific biochemical and biophysical mechanisms to explain Af3 pathology, The strongest in vivo evidence comes from a large body of work demonstrating that injection of misfolded Af3 from either biological or synthetic sources at specific loci in the brains of AD model mice accelerates the appearance of aggregated, transgenically expressed Af3 throughout the brain. 42 ,59-62 While these seed-induced Af3 deposits are initially observed in tissue directly surrounding sites of seeding, spreading eventually occurs along axonally connected regions and in separate locations, suggesting that both axonal transport and extracellular routes playa role in the spreading of Af3 throughout the brain.
Building on this substantial body of in vivo data are several lines of in vitro biochemical and biophysical investigation that have provided direct evidence for specific mechanisms in the propagation of Af3 misfolding. Researchers throughout the AD field have long noted anecdotally that purified Af3 often seems to behave in unpredictable ways that suggest an aggregation mechanism capable of following multiple paths, These suspicions were recently confirmed when aliquots of monomeric Af3 from a single pool were aggregated separately, leading to formation of many structurally and immunologically distinct, aliquot-specific Af3 oligomers,63 These experiments also demonstrated that exposing specific preformed Af3 oligomer species to monomeric Af3 promotes the aggregation of monomers into oligomeric species of the same size range and immunoreactivity. A straightforward interpretation of these data suggests a model in which the specific folding patterns of oligomers formed early in the aggregation process self-propagate by increasing the probability of similar folding patterns occurring in newly formed oligomers.
While We recently described a specific, prion-like mechanism of "intermolecular infectivity" involving A[33(pE)-42,9 which lacks the first two amino acids found in A[3l-40 and A[3l-42, and whose initial residue is enzymatically modified from glutamate to pyroglutamylate (pE) by glutaminyl cyclase. 68 The in vivo relevance of these results was established by multiple lines of additional evidence. Most notably, putative dimers and trimers containing both conventional and pE-modified A[3 species were detected more commonly in brain cytosol collected post-mortem from AD patients than from normal age-matched controls, and transgenic mice that produced A[33 (pE) -x experienced massive gliosis and neuron death in the hippocampus by www.landesbioscience.com Prion Pre-aggregated tau, comprising filaments and apparent oligomers, is able to enter cultured cells and then cause the intracellular tau that they express to misfold and aggregate as well, 75, 76 This general principle has also been demonstrated in vivo through experiments showing that intracerebral injection of aggregationprone P301S mutant tau can induce the spreading ofNFT formation throughout the cortex of mice expressing wild-type human tau, which does not form NFTs spontaneously.35 Given the small amount of initially injected material in these experiments, the data indicate that WT human tau was able to adopt at least some critical properties of the aggregated, mutant human tau to continue propagation throughout the brain. The aforementioned studies of P301L tau being expressed exclusively in the EC of transgenic mice, but driving tau pathology into hippocampal structures 36 ,38 constitute further evidence for prion-like behavior of misfolded tau.
Tau as a Prion
The possibility that tau oligomers serve as agents for the spread of tau pathology must be seriously considered as well. Such oligomers have been detected immunologically in AD brain, most notably in neurons that had not yet accumulated NFTs.73.77 Furthermore, intracerebral injection of tau oligomers, but neither monomeric nor fibrillar tau, has been shown to be neurotoxic, to cause synaptic and mitochondrial dysfunction, and to impair memory.78 There is also evidence, though, for a direct pathogenic connection between AI3 and tau. In the absence of any other proteins or peptides, AI3 can bind to tau 43 and tau monomers can be induced to oligomerize in vitro after exposure to low substoichiometric levels of AI3 0ligomers. 44 These findings raise the obvious possibility that, in vivo, AI3 oligomers seed the initial formation of tau oligomers, which can then self-propagate in the absence of additional input from AI3 (Fig. 1 ). If such a phenomenon were to occur in vivo, it would represent a seminal step in AD pathogenesis. It might explain, moreover, why so many heroic efforts to target AI3 therapeutically in clinical trials have failed so far. This may be because all experimental patients in such trials must first have received a clinical diagnosis of AD, which can only be made long after tau pathology is already well underway and self-sustaining.
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